I-Mab Stock Price, News & Analysis

I-Mab (NASDAQ: IMAB) announced it will present Phase 1 optimized dose estimation data for givastomig (TJ033721/ABL111) at SITC 2024. The presentation focuses on this novel first-in-class Claudin18.2 and 4-1BB bispecific antibody for cancer treatment. The poster presentation, numbered 1474, will take place on November 9, 2024, at the George R. Brown Convention Center in Houston, Texas, during the Society for Immunotherapy of Cancer conference. The poster details optimal dose estimation using an integrated approach from Phase 1 data and will be available on I-Mab's website under the 'Innovation, Publications & Presentations' section.

I-Mab (NASDAQ: IMAB), a US-based global biotech company focused on cancer immunotherapies, has announced its participation in the Truist Securities BioPharma Symposium on November 7, 2024. The company's management team, including Interim CEO Sean Fu, CFO Joe Skelton, CMO Phillip Dennis, and Senior Director of Investor Relations Tyler Ehler, will engage in one-on-one and small group meetings with investors during the event.

I-Mab (NASDAQ: IMAB) presented updated Phase 1 data for givastomig, a novel Claudin 18.2 X 4-1BB bispecific antibody immunostimulant, at ESMO 2024. The study showed promising single-agent activity in heavily pre-treated gastric cancer patients with varying Claudin 18.2 expression levels. Key findings include:

- Recommended Phase 2 dose: 8-12 mg/kg
- Well-tolerated up to highest study doses
- Objective response rate (ORR): 16.3% (7/43 patients)
- Disease control rate (DCR): 48.8% (21/43 patients)
- No dose-limiting toxicity up to 15 mg/kg Q2W and 18 mg/kg Q3W
- Linear pharmacokinetics at doses ≥5 mg/kg

A Phase 1b study combining givastomig with standard-of-care treatment in front-line gastric cancer patients is ongoing, with results expected in H2 2025.

I-Mab (NASDAQ: IMAB) presented positive pharmacokinetics data for uliledlimab, a CD73-targeting antibody, at the 2024 World Conference on Lung Cancer. The data, derived from three Phase 1 studies, supports dosing strategies for upcoming clinical trials. Key findings include:

- 95% of the simulated population achieved target threshold with 30 mg/kg of uliledlimab
- Positive correlation between uliledlimab concentration and overall response rate probability in mNSCLC patients
- CD73 receptor occupancy in peripheral B cells reached and maintained at 90% or above
- 30 mg/kg dose with a single boost on C1D8 maintained target concentration of 80 μg/mL

A randomized Phase 2 study of uliledlimab combined with pembrolizumab and chemotherapy is expected to begin in 1H 2025.

I-Mab reported its 1H 2024 financial results and provided pipeline updates:

• Completed divestiture of China operations
• Received IND clearance for uliledlimab (CD73 antibody) in first-line mNSCLC
• Entered clinical collaboration with Bristol Myers Squibb for givastomig (CLDN18.2 X 4-1BB bispecific) in gastric cancer
• Presented encouraging early data for ragistomig (PD-L1 X 4-1BB bispecific) at ASCO 2024
• Cash position of $207.5 million as of June 30, 2024, with runway into 2027
• Net loss from continuing operations of $17.8 million for 1H 2024
• No revenue generated in 1H 2024
• R&D expenses of $10.8 million and administrative expenses of $14.3 million for 1H 2024

I-Mab (NASDAQ: IMAB), a US-based global clinical-stage biotech company focused on developing immunotherapies for cancer treatment, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024. The company's management team, including Interim CEO Sean Fu and CMO Phillip Dennis, will present at 5:00 PM ET.

The event will also feature one-on-one and small group meetings from September 9-10, with additional management participants including CFO Joe Skelton and Senior Director of Investor Relations Tyler Ehler. A webcast of the presentation will be available on I-Mab's IR website under the 'Event Calendar' section.

I-Mab (NASDAQ: IMAB), a US-based global biotech company focused on developing immunotherapies for cancer treatment, has announced it will release its 1H 2024 financial results on August 28, 2024. The company will host a conference call and webcast at 8:00 AM ET on the same day to discuss financial results, pipeline progress, and recent business highlights for the half year ended June 30, 2024.

Investors and analysts can join the conference call via domestic (1-877-407-0784) or international (1-201-689-8560) dial-in numbers, using the Conference ID: 13747695. A webcast link is also provided. The Call me™ link will be active 15 minutes before the scheduled start time. A replay of the call will be available on the I-Mab website's Investor Relations page for 6 months.

I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company focused on cancer immunotherapies, has appointed PricewaterhouseCoopers LLP (PwC US) as its independent registered public accounting firm for fiscal year 2024. This decision, approved by the Audit Committee, is part of I-Mab's strategic transition to become a fully U.S.-based biotech company. The change aims to ensure compliance with the Holding Foreign Companies Accountable Act and aligns with the company's long-term growth objectives.

Interim CEO Sean Fu emphasized that this appointment marks a significant milestone in I-Mab's U.S. transition strategy. CFO Joseph Skelton expressed enthusiasm about working with PwC US, viewing it as beneficial for shareholders. The company assures that this transition was not due to any disagreements or issues with the previous auditor.

I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company, has announced significant leadership changes. Mr. Wei Fu has been appointed as the new Chairman of the Board, replacing Dr. Pamela M. Klein. Mr. Raj Kannan is stepping down as CEO and board member, with Dr. Sean Xi-Yong Fu taking over as Interim CEO and joining the board. Dr. Fu brings extensive experience from various biotech roles, including his position as an Operating Partner at ABio-X and former CEO of RVAC Medicines.

The company also announced changes to its Board of Directors and committees, including the resignations of Dr. Ruyi He and Professor Rong Shao. These transitions aim to strengthen I-Mab's leadership as it continues its transformation into a U.S.-based biotech company, focusing on advancing its R&D pipeline and creating value for shareholders.